Key statistics
On Friday, Aligos Therapeutics Inc (ALGS:NAQ) closed at 10.19, 50.74% above the 52 week low of 6.76 set on Oct 08, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 9.87 |
---|---|
High | 10.41 |
Low | 9.68 |
Bid | 9.80 |
Offer | 10.40 |
Previous close | 9.92 |
Average volume | 136.50k |
---|---|
Shares outstanding | 3.20m |
Free float | 2.46m |
P/E (TTM) | -- |
Market cap | 32.57m USD |
EPS (TTM) | -25.99 USD |
Data delayed at least 15 minutes, as of Nov 08 2024 21:00 GMT.
More ▼
- Aligos Therapeutics Reports Recent Business Progress and Third Quarter 2024 Financial Results
- Aligos Therapeutics to Announce 3rd Quarter 2024 Financial Results on November 6, 2024
- Aligos Therapeutics Announces U.S. FDA Clearance of IND Application for ALG-000184
- Aligos Therapeutics Announces Acceptance of Abstracts on Incremental Data from ALG-000184 in CHB Subjects and Late-Breaker Oral Presentation of Data from the Phase 2a HERALD Study of ALG-055009 in MASH Subjects at The Liver Meeting (TLM) 2024
- Aligos Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
- Aligos Therapeutics Appoints David Perry as Vice President of Business Development
- Aligos Therapeutics to Present at Investor Conferences in October
- Aligos Therapeutics Strengthens Senior Leadership Team with the Appointment of Hardean Achneck, MD as Chief Medical Officer
- Aligos Therapeutics Announces Positive Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH
- Aligos Therapeutics to Announce Topline Results from the Phase 2a HERALD Study of ALG-055009 for the Treatment of MASH on September 19, 2024
More ▼